Piper Sandler lowers Zions Bancorp stock price target on loan issues

Published 16/10/2025, 12:34
Piper Sandler lowers Zions Bancorp stock price target on loan issues

Investing.com - Piper Sandler reduced its price target on Zions Bancorp (NASDAQ:ZION) to $59.00 from $62.00 on Thursday, while maintaining a Neutral rating on the stock. The $8 billion market cap bank, currently trading at a P/E ratio of 3.97, has maintained dividend payments for an impressive 55 consecutive years, with a current yield of 3.33%.

The adjustment follows Zions Bancorp’s disclosure that it discovered legal actions taken by multiple banks and lenders against parties connected to two commercial and industrial loan borrowers from its CB&T division.

Upon internal review, the bank uncovered apparent misrepresentations and irregularities related to these loans, prompting Zions to take a $60 million provision for the full relationship and charge off $50 million of the outstanding amount.

Piper Sandler adjusted its third-quarter 2025 earnings per share estimate for Zions to $1.20 from $1.51 to reflect the outsized loan loss provision, while maintaining its fourth-quarter and 2026 estimates at $1.54 and $5.90, respectively.

The research firm’s new price target reflects a 10.0x multiple on estimated 2026 earnings, down from 10.5x previously, representing a slight discount to peers as credit concerns are expected to remain a near-term overhang for the stock.

In other recent news, Zions Bancorporation announced a strong financial performance for the second quarter of 2025, reporting net earnings of $243 million, which marks a 28% increase compared to the same period last year. The company’s diluted earnings per share (EPS) rose to $1.63, up from $1.13 in the previous year. Zions Bancorporation’s net interest margin expanded for the sixth consecutive quarter, reflecting a positive trend for the bank. Despite a modest decline in premarket trading, the stock demonstrated resilience during the trading day. These developments underscore the bank’s financial health and growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.